Surgery Partners (SGRY)
(Delayed Data from NSDQ)
$24.55 USD
-0.29 (-1.17%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $24.53 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Surgery Partners (SGRY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$42.36 | $50.00 | $35.00 | 70.53% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Surgery Partners comes to $42.36. The forecasts range from a low of $35.00 to a high of $50.00. The average price target represents an increase of 70.53% from the last closing price of $24.84.
Analyst Price Targets (11)
Broker Rating
Surgery Partners currently has an average brokerage recommendation (ABR) of 1.45 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.45 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 72.73% and 9.09% of all recommendations. A month ago, Strong Buy made up 72.73%, while Buy represented 9.09%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 9 | 9 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.45 | 1.45 | 1.45 | 1.27 | 1.27 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/5/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
3/1/2024 | The Benchmark Company | William Sutherland | Strong Buy | Strong Buy |
11/8/2023 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
11/7/2023 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.45 |
ABR (Last week) | 1.45 |
# of Recs in ABR | 11 |
Average Target Price | $42.36 |
LT Growth Rate | 14.00% |
Industry | Medical Services |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | 0.07 |